The initiation of coverage by B of A Securities with an Underperform rating suggests a bearish outlook on Madrigal Pharmaceuticals. The set price target of $150 provides a specific expectation for the stock's future performance, which could influence investor sentiment and potentially lead to a decrease in stock price in the short term.